Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
General Rheumatology
•
Infectious Disease
Should we feel comfortable starting anti-TNF therapy in an otherwise low risk patient with borderline IGRA?
Should a CXR be pursued? Is there a difference in sensitivity/specificity of different IGRAs?
Related Questions
When is it safe to resume DMARDs in a patient who was diagnosed with active TB and started on treatment?
What isolation policies are Rheumatology offices employing for both staff and patients diagnosed with COVID-19 given the new CDC guidelines?
What is the optimal timing for Zoster vaccine administration for a patient who recently recovered from herpes zoster infection and is now planning to start B-cell depletion therapy?
What else do you consider in the differential diagnosis for pulmonary-renal syndromes if there is low clinical and serologic evidence of AAV, Goodpasture's or other rheumatologic disease (SLE, RA, APS, Scleroderma)?
How do you approach ongoing screening for TB in patients with a history of treated latent TB, but who have ongoing use of DMARDs and/or biologics given Quantiferon testing and PPD can remain positive?
What is your approach to working up diarrhea in an immunocompromised patient?
How do you approach immunosuppression in patients with a positive Interferon Gamma Release Assay and prior intravesicular BCG treatment for bladder cancer?
What is your approach to a patient on immunosuppressants with an outpatient cutaneous MRSA infection or to a MRSA carrier?
How do you approach management of patients with active RA and recurrent non-severe C.diff?
How do you approach endocarditis prophylaxis for patients with rheumatic diseases undergoing invasive dental surgery and no history of joint replacement?